Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate versus phenytoin monotherapy in new-onset epilepsy
2015-001222-42Phase 3
- Sponsor
- Johnson & Johnson
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of topiramate and phenylephrine in epilepsy (2 arms), sponsored by Johnson & Johnson. Primary endpoints: Time to first seizure during the double-blind phase and Proportion of patients seizure free.
02
Drugs
topiramatephenylephrine
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2015-001222-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001222-42.